1.       Adamson DL, Nelson-Piercy C. Managing diabetes during pregnancy. BMJ. 2004;329(7460):1297-1300.

2.       Aldudak B, Yıldırım A, Tavil B, et al. Cardiomyopathy in Friedreich ataxia: pediatric echocardiographic follow-up and clinical correlation. Anadolu Kardiyol Derg. 2015;15(3):206-211. doi:10.5152/akd.2015.5914

3.       American Diabetes Association. Children and adolescents: standards of medical care in diabetes—2022. Diabetes Care. 2022;45(Suppl 1):S208–S231.

4.       Arad M, et al. Glycogen storage diseases presenting with cardiac manifestations. Eur J Pediatr. 2007;166(4):319–324.

5.       Baker RD, Greer FR. Diagnosis and prevention of iron deficiency and iron-deficiency anemia in infants and young children. Pediatrics. 2010;126(5):1040–1050.

6.       Barbosa MM, et al. Cardiovascular magnetic resonance in children and adolescents with sickle cell anemia: evaluation of cardiac iron overload and function. J Cardiovasc Magn Reson. 2013;15:83.

7.       Beard JL, Connor JR. Iron status and neural functioning. Annu Rev Nutr. 2003;23:41–58.

8.       Beutler E, Grabowski GA. Gaucher Disease. In: The Metabolic and Molecular Bases of Inherited Disease. 8th ed. McGraw-Hill; 2001.

9.       Boney CM, et al. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics. 2005;115(3):e290-e296.

10.   Braunlin EA. Cardiac involvement in mucopolysaccharidoses. Cardiol Young. 2005;15(Suppl 1):142–146. doi:10.1017/S104795110500364X

11.    Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM. Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum. 2002;46(2):436-444. doi:10.1002/art.10083

12.   Cabral CHC, et al. Iron deficiency anemia and its impact on cardiac function in children with congenital heart disease. Arq Bras Cardiol. 2008;91(6):408–413.

13.   Cardinale D, et al. Biomarkers and imaging in the diagnosis and management of chemotherapy-induced cardiotoxicity. Eur Heart J. 2020;41(14):1372–1380.

14.   Carver JR, et al. Prevention of cardiac toxicity in cancer survivors. J Clin Oncol. 2007;25(25):4113–4118.

15.    Chen YT, et al. Glycogen storage diseases. In: Valle D, et al., editors. The Online Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill; 2019.

16.   Chertow GM, et al. Mineral metabolism and vascular calcification in dialysis patients. Kidney Int. 2005;67(6):2295–2303.

17.   Chung S, et al. Cardiovascular consequences of iron deficiency in children. Pediatr Cardiol. 2012;33(2):256–261.

18.   Dabelea D, et al. Type 2 diabetes mellitus in children and adolescents: the search for new risk factors. J Pediatr. 2005;146(4):453-459.

19.   Davies RR, et al. Surgical management of aortic root disease in Marfan syndrome: a multicenter experience. J Thorac Cardiovasc Surg. 2007;133(6):1344–1350.

20.   DP, Dietz HC. Marfan's syndrome. Lancet. 2005;366(9501):1965–1976.

21.    Duburcq T, et al. Role of cardiac imaging in glycogen storage diseases. Arch Cardiovasc Dis. 2020;113(7-8):462–471.

22.   Erickson RP. Benefits of early treatment in Duchenne muscular dystrophy: evidence from current studies. Pediatr Drugs. 2002;4(11):735–739.

23.   Finsterer J, Stöllberger C. The heart in human dystrophinopathies. Cardiology. 2003;99(1):1–19.

24.   Fisher DA. Hypothyroidism in infancy and childhood. Adv Pediatr. 1978;25:349-368.

25.   Flynn JT. Evaluation and management of hypertension in childhood nephritis. Pediatr Nephrol. 2010;25(8):1441–1450.

26.    Friedman JM, Arbiser J, Epstein JA, et al. Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med. 2002;4(3):105–111.

27.   Goldenberg J, et al. Symptomatic cardiac involvement in juvenile rheumatoid arthritis. Int J Cardiol. 1992;34(1):57–62.

28.   Goodman WG, London G, Amann K, et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis. 2004;43(3):572–579.

29.   Gökçe N, et al. Cardiovascular disease risk factors in children with chronic kidney disease. Pediatr Nephrol. 2003;18(9):892–898.

30.    Groh WJ. Arrhythmias and sudden death in myotonic dystrophy. Heart Rhythm. 2012;9(8):1251–1254.

31.   Haller MJ, et al. Diabetic cardiovascular disease in children. Endocrinol Metab Clin North Am. 2004;33(3):621-641.

32.    Hankins JS, et al. Cardiac abnormalities in children with sickle cell disease. Am J Hematol. 2008;83(6):505–510.

33.    Harding CO, Pagon RA. Incidence of cardiac rhabdomyoma in tuberous sclerosis complex. Am J Med Genet. 1990;37(4):443–446.

34.   Harmatz PR, Giugliani R, Schwartz IV, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux–Lamy syndrome). J Pediatr. 2006;148(4):533–539. doi:10.1016/j.jpeds.2005.12.020

35.   Hersh AO, Trivedi B, Kimura Y. Childhood-onset systemic lupus erythematosus: a review of the literature. Curr Rheumatol Rep. 2021;23(6):39. doi:10.1007/s11926-021-00993-8

36.   Hogg RJ, et al. Chronic kidney disease in children: clinical practice recommendations for screening, diagnosis, and management. Kidney Int. 2003;63(Suppl 83):S126–S131.

37.   Hogg RJ, Portman RJ. Cardiovascular effects of glomerulonephritis in children. Pediatr Nephrol. 1992;6(3):250–258.

38.    Izmirly PM, Saxena A, Kim MY, et al. Maternal autoantibodies are associated with structural congenital heart block in neonatal lupus. J Am Coll Cardiol. 2011;57(6):715-723. doi:10.1016/j.jacc.2010.07.053

39.    Järvisalo MJ, et al. Cardiovascular organ damage in children with type 1 diabetes. Circulation. 2002;106(17):2194-2199.

40.   Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. Endocr Rev. 2005;26(5):704–728.

41.   Kishnani PS, et al. Pompe disease diagnosis and management guideline. Genet Med. 2006;8(5):267–288.

42.   Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007;116(15):1725-1735.

43.   Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007;116(15):1725-1735.

44.   Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344(7):501–509.

45.   Laurent V, et al. Cardiac involvement in myotonic dystrophy. Arch Cardiovasc Dis. 2011;104(3):164–170.

46.   Liberman HA, Pastores GM. Cardiac involvement in Gaucher disease. Blood Cells Mol Dis. 2010;44(1):54–60.

47.    Lin AE, Birch PH, Korf BR, et al. Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1. Am J Med Genet. 2000;95(2):108–

48.   Lipshultz SE, et al. Long-term cardiovascular toxicity in children and young adults after cancer therapy. J Clin Oncol. 2013;31(10):1223–1231.

49.   Litwin M, et al. Intima-media thickness and arterial elasticity in hypertensive children with CKD. Pediatr Nephrol. 2004;19(5):537–543.

50.   Lund MB, et al. Cardiac MRI in the evaluation of cancer patients with suspected cardiotoxicity. JACC Cardiovasc Imaging. 2014;7(9):874–885.

51.   Maceira AM, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. JACC. 2005;45(6):903–910.

52.    Mancini DM, et al. Effect of iron deficiency on exercise tolerance and cardiac function in patients with heart failure. J Am Coll Cardiol. 2003;41(9):1440–1446.

53.   Matteucci MC, et al. Left ventricular hypertrophy in children with chronic renal failure. J Pediatr. 2003;143(5):673–679.

54.   McDonald SP, Craig JC. Long-term survival of children with end-stage renal disease. N Engl J Med. 2004;350(26):2654–2662.

55.    McNally EM, et al. Genetic mutations and mechanisms in cardiomyopathy in Duchenne and Becker muscular dystrophy. J Clin Invest. 2007;117(3):865–872.

56.   Mistry PK, et al. Gaucher disease: Progress and ongoing challenges. Mol Genet Metab. 2017;120(1–2):8–21.

57.   Mitsnefes MM. Cardiovascular complications of pediatric chronic kidney disease. Pediatr Nephrol. 2008;23(1):27-39.

58.    Motta I, Cappellini MD. Gaucher disease and heart involvement. J Inborn Errors Metab Screen. 2016;4:1–6.

59.   Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford). 2011;50(Suppl 5):v4–v12. doi:10.1093/rheumatology/ker394

60.   Mulrooney DA, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;339:b4606.

61.   Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Valle D, Beaudet AL, Vogelstein B, et al, eds. The Online Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill; 2001. doi:10.1036/ommbid.223

62.    Nguyen HH, Wolfe JT. Echocardiographic findings in children with myotonic dystrophy. Pediatr Cardiol. 2003;24(3):241–246.

63.    Nigro G, et al. Evolution of cardiomyopathy in Duchenne and Becker muscular dystrophy. J Pediatr. 1990;117(1 Pt 1):144–150.

64.   Nijmeijer SCM, de Bruin-Bon RHACM, Wijburg FA, et al. Cardiac disease in mucopolysaccharidosis type I, II and VI. Mol Genet Metab. 2019;126(2):107–112. doi:10.1016/j.ymgme.2018.08.010

65.    Northrup H, Krueger DA. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):243–254.

66.   Oderich GS, Sullivan TM, Bower TC, et al. Vascular abnormalities in neurofibromatosis syndrome type I: clinical spectrum, management, and results. J Vasc Surg. 2007;46(3):475–484.

67.   Perry RJ, et al. Neonatal thyrotoxicosis: clinical features and management. Arch Dis Child Fetal Neonatal Ed. 2002;86:F111–F114.

68.   Petri H, et al. Increased risk of AV conduction defects in patients with myotonic dystrophy: a nationwide study. Eur Heart J. 2010;31(9):1042–1048.

69.   Polikar R. Thyroid and the heart. Circulation. 1993;87(5):1435–1441.

70.   Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030–1043.

71.   Reynen K. Cardiac involvement in hematologic malignancies. Heart. 2004;90(3):324–330.

72.   Richards S, et al. Standards and guidelines for the interpretation of sequence variants. Genet Med. 2015;17(5):405–424.

73.    Rivkees SA. Pediatric Graves’ disease: controversies in management. Horm Res Paediatr. 2010;74(5):305–311.

74.    Rizzo T, et al. Neonatal cardiac abnormalities associated with maternal diabetes mellitus. J Pediatr. 1991;118(4 Pt 1):561-566.

75.    Roman MJ, et al. Aortic root dilatation and the Marfan syndrome. N Engl J Med. 1993;329(19):1335–1341.

76.   Ross DS. Hyperthyroidism, thyroid hormone therapy, and cardiovascular function. Am J Med. 1994;96(6):642–648.

77.   Rossetto E, et al. Cardiac involvement in juvenile idiopathic arthritis. Pediatr Rheumatol. 2013;11(Suppl 2):P56.

78.   Russo V, et al. Pacemaker and implantable cardioverter-defibrillator therapy in patients with myotonic dystrophy: a long-term follow-up. J Cardiovasc Med. 2008;9(11):1246–1250.

79.   Saleeb SF, Agarwal S, Knox J, et al. Libman-Sacks endocarditis: detection, characterization, and clinical correlates by transesophageal echocardiography. Circulation. 2005;111(9):1123-1129. doi:10.1161/01.CIR.0000157146.59281.3D

80.   Sawin CT, et al. The aging thyroid: relationship between subclinical hypothyroidism, cardiac function, and serum lipids in elderly. JAMA. 1985;254(3):333–335.

81.   Schmid J, et al. Cardiac involvement in myotonic dystrophy type 1: a cohort study. Int J Cardiol. 2012;154(1):59–63.

82.    Silversides CK, et al. Cardiac imaging and outcome in Duchenne muscular dystrophy. J Am Coll Cardiol. 2004;43(5):823–828.

83.   Sinha MD, et al. Electrocardiographic findings in pediatric nephrology patients. Pediatr Nephrol. 2006;21(4):547–553.

84.   Slonim AE, et al. Danon disease: clinical features and molecular genetics. Curr Opin Pediatr. 2002;14(6):653–659.

85.   Tarshish P, et al. Clinical features of myocarditis in poststreptococcal glomerulonephritis. J Pediatr. 2001;138(3):403–406.

86.   Tayebi N, et al. Recurring mutation D409H and cardiac calcifications in type III Gaucher disease. Am J Med Genet A. 2003;116A(2):170–175.

87.    Thavendiranathan P, et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy. J Am Coll Cardiol. 2014;63(25):2751–2768.

88.   Thrush PT, et al. Electrocardiographic changes and arrhythmias in boys with Duchenne muscular dystrophy. J Pediatr. 2013;162(1):185–191.

89.   Tsou AY, Paulsen EK, Lagedrost SJ, et al. Mortality in Friedreich ataxia. J Neurol Sci. 2011;307(1-2):46-49. doi:10.1016/j.jns.2011.04.002

90.    van Dalen EC, et al. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011;(6):CD003917.

91.   Van der Ploeg AT, et al. Enzyme replacement therapy for Pompe disease. Lancet. 2010;375(9719):2136–2143.

92.   Vetter VL, et al. Pediatric Holter monitoring: indications and interpretations. Curr Opin Cardiol. 2014;29(1):93–98.

93.   Vinik AI, et al. Diabetic autonomic neuropathy. Diabetes Care. 2003;26(5):1553-1579.

94.   Voskaridou E, et al. Pulmonary hypertension and left ventricular diastolic dysfunction in sickle cell disease. Br J Haematol. 2012;157(5):677–682.

95.   Weidemann F, Rummey C, Bijnens B, et al. The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms. Circulation. 2012;125(13):1626-1634. doi:10.1161/CIRCULATIONAHA.111.042457

96.   Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–2247.

97.    Yetman AT, Bornemeier RA, McCrindle BW. Usefulness of beta-blocker therapy in the prevention of aortic complications in Marfan syndrome. Am J Cardiol. 2003;91(5):619–621.

98.    Yetman AT, et al. Cardiovascular complications in pediatric Marfan syndrome. Pediatr Cardiol. 2003;24(5):452–455.

99.   Young L, et al. Cardiac manifestations of PRKAG2 mutation. Circ Cardiovasc Genet. 2011;4(1):51–59.

100.                      Zamorano JL, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity. Eur Heart J. 2016;37(36):2768–2801.